Filter posts

BIO’s Tom DiLenge Testifies on Biotechnology Innovation Ecosystem before House E&C #SubHealth

At a hearing today held by the House Energy and Commerce Subcommittee on Health on …

Insurers Distort the Facts on Drug Costs … Again

An effort by the Blue Cross Blue Shield Association (BCBSA) to spur a discussion on …

A New Approach to Assessing Value in Health Care

It’s an important and exciting time in the biotech industry. Spending on prescription drugs has …

Jim Greenwood Talks Biotech Innovation With Bloomberg Radio

While in Boston this week, BIO CEO Jim Greenwood sat down with Bloomberg Boston Bureau …

What's Driving Health Care Spending? Hint: Not Drug Costs.

With health care costs an important concern for many Americans, a common misperception is the …

Blaming Pharma Won’t Lower Health Care Costs

This week, the USA Today Editorial Board took aim at the pharmaceutical industry in a new piece: Stop …

A Discussion on Value at #BIF17

In a recent op-ed, BIO President and CEO Jim Greenwood wrote about a promising trend …

ICYMI: Drug Development is Complicated. Let’s Start with the Facts.

Here’s a fact you might not have known: 90% of drug development programs fail. Yet …

BIO 2017 Patient and Health Advocacy Summit Explores Best Practices in State Advocacy

The first day of BIO’s Patient Health & Advocacy Summit concluded with a breakout session …

Three Encouraging Steps on Prescription Drug Costs

It’s a refrain you hear often in the news: Drug costs are soaring and nothing …